A detailed history of Baker Bros. Advisors LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Baker Bros. Advisors LP holds 42,877,916 shares of ACAD stock, worth $689 Million. This represents 9.26% of its overall portfolio holdings.

Number of Shares
42,877,916
Previous 42,864,612 0.03%
Holding current value
$689 Million
Previous $793 Million 12.09%
% of portfolio
9.26%
Previous 10.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $194,504 - $245,059
13,304 Added 0.03%
42,877,916 $697 Million
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $16.5 Million - $23.8 Million
926,126 Added 2.21%
42,864,612 $1.03 Billion
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $244,800 - $313,800
15,000 Added 0.04%
41,938,486 $789 Million
Q2 2022

Aug 15, 2022

BUY
$13.01 - $27.22 $166,293 - $347,926
12,782 Added 0.03%
41,923,486 $591 Million
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $153,072 - $336,428
6,118 Added 0.01%
41,910,704 $1.08 Billion
Q1 2020

May 15, 2020

BUY
$31.65 - $46.87 $33.2 Million - $49.2 Million
1,050,000 Added 2.57%
41,904,586 $1.77 Billion
Q3 2019

Nov 14, 2019

BUY
$22.22 - $44.01 $34.7 Million - $68.8 Million
1,562,500 Added 3.98%
40,854,586 $1.47 Billion
Q2 2019

Aug 14, 2019

SELL
$23.32 - $28.12 $9.84 Million - $11.9 Million
-421,756 Reduced 1.06%
39,292,086 $1.05 Billion
Q4 2018

Feb 13, 2019

BUY
$14.32 - $22.92 $161 Million - $258 Million
11,274,728 Added 39.65%
39,713,842 $642 Million
Q3 2018

Nov 14, 2018

BUY
$13.03 - $21.81 $15.8 Million - $26.4 Million
1,210,776 Added 4.45%
28,439,114 $590 Million
Q4 2017

Feb 14, 2018

BUY
$26.84 - $39.14 $37.8 Million - $55.1 Million
1,408,570 Added 5.46%
27,228,338 $820 Million
Q3 2017

Nov 14, 2017

BUY
$29.49 - $38.37 $761 Million - $991 Million
25,819,768
25,819,768 $973 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.6B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.